Since the world of Alzheimer’s therapeutics hasn’t seen much practical benefit from targeting harmful proteins like amyloid-beta, maybe other approaches like targeting dysfunctional mitochondria are worth exploring in more depth. Apparently, improving mitochondrial function can decrease plaque burden and improve cognition in a mouse model. Why do cancer survivors have shorter lifespans than the rest

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD